Grant: Engage Grants Program
University of Toronto
$25,000.00
Gold Nanotechnology for Delivery of OCZ103
FY 2012-13
Summary
Oncozyme Pharma Inc. is uniquely focused on the treatment of cancer via development of drugs that target
DNA repair enzymes such as endo-exonucleases. Studies conducted by Oncozyme have identified a series of
potent inhibitors (OCZ compounds) of a key endo-exonuclease enzyme resulting in synergistic effects when
administered in combination with chemotherapy. However, to this point, the success of the OCZ compounds,
as modulators of chemotherapy, has been limited due to their non-selective distribution in vivo. The proposed
research addresses this shortcoming through the development of gold nanotechnology engineered to selectively
deliver the OCZ compounds to solid tumors. Gold has been selected as the material of choice for fabrication of
the nanotechnology due to its high atomic number (Au, Z = 79) which also enables it to serve as an effective
radiosensitizer. Recent pilot studies by Oncozyme Pharma Inc. (unpublished data) have shown that the OCZ
compounds also have activity as radiosensitizers. Given that the OCZ compounds and gold exert their
sensitization effects by different mechanisms, the combination of the OCZ compounds and gold
nanotechnology on radiotherapy is likely to be strongly synergistic. Therefore, the gold nanotechnology to be
designed in this research is not only to provide selective delivery of OCZ compounds to solid tumors,
moreover, the powerful OCZ-gold combination creates a new approach with the potential to completely
transform the effectiveness of radiation therapy.
Program
Engage Grants Program
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
446070-2012
Name nom
Allen, Christine
Department département
Pharmacy, Leslie Dan Faculty of
Organization id
31
Institution établissement
University of Toronto
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2012
Competition year année de concours
2012
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1553
Committee name en
Ontario Internal Decision Committee
Committee name fr
Comité de décision interne pour l'Ontario
Area of application code
1211
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Medical and health sciences
Area of application fr
Sciences médicales et de la santé
Research subject code
2000
Research subject group en
Materials science and technology
Research subject group fr
Science et technologie des matériaux
Research subject en
Materials science and technology
Research subject fr
Science et technologie des matériaux
Partie
1
Nb partie
1
Application title
Gold Nanotechnology for Delivery of OCZ103
Keyword
NSERC
Application summary
Oncozyme Pharma Inc. is uniquely focused on the treatment of cancer via development of drugs that target
DNA repair enzymes such as endo-exonucleases. Studies conducted by Oncozyme have identified a series of
potent inhibitors (OCZ compounds) of a key endo-exonuclease enzyme resulting in synergistic effects when
administered in combination with chemotherapy. However, to this point, the success of the OCZ compounds,
as modulators of chemotherapy, has been limited due to their non-selective distribution in vivo. The proposed
research addresses this shortcoming through the development of gold nanotechnology engineered to selectively
deliver the OCZ compounds to solid tumors. Gold has been selected as the material of choice for fabrication of
the nanotechnology due to its high atomic number (Au, Z = 79) which also enables it to serve as an effective
radiosensitizer. Recent pilot studies by Oncozyme Pharma Inc. (unpublished data) have shown that the OCZ
compounds also have activity as radiosensitizers. Given that the OCZ compounds and gold exert their
sensitization effects by different mechanisms, the combination of the OCZ compounds and gold
nanotechnology on radiotherapy is likely to be strongly synergistic. Therefore, the gold nanotechnology to be
designed in this research is not only to provide selective delivery of OCZ compounds to solid tumors,
moreover, the powerful OCZ-gold combination creates a new approach with the potential to completely
transform the effectiveness of radiation therapy.